Japanese Drug Industry Makes Another Billion-Dollar U.S. Buy
Posted by Jacob Goldstein
ShionogiYet another Japanese drugmaker is dropping lots of cash to buy its way into the US drug business. This time it’s Shionogi, which is buying Sciele Pharma, a small, publicly traded drug maker based in Atlanta. The all-cash deal is worth $1.42 billion, the WSJ says.
Earlier this year, Takeda a huge player in Japan’s pharma universe, spent about $9 billion to buy Millennium Pharmaceuticals; and last year, Eisai spent nearly $4 billion billion to buy MGI.
Those recent precedents suggest Shionogi’s buy may be motivated in part by “yoko-narabi ishiki” — the desire to stay in line with the group — WSJ’s Japanese pharma guru Peter Landers tells the Health Blog.
Shionogi is perhaps best known internationally as the discoverer of Crestor, a cholesterol drug marketed by AstraZeneca in most of the world. The company’s research pipeline includes treatments for HIV, allergies and obesity, the WSJ says.
“As we make sound progress in research and development, we definitely want to establish a marketing operation in the world’s largest market — the U.S.,” Shionogi President Isao Teshirogi reportedly said at a news conference.
Shionogi’s $31 per share offer represents a 57% premium over Sciele share’s average price in the past six months. Sciele’s management is backing the deal, and the company’s stock is up more than 50% today on the news. [标签:content1][标签:content2]
作者:admin@医学,生命科学 2011-01-25 05:14